Abstract
In recent years, several therapeutic advances have been made in squamous cell carcinoma of the head and neck (SCCHN). However, despite multimodality therapy, patients with locally advanced SCCHN continue to demonstrate suboptimal 5-year survival rates. The addition of novel, targeted agents to traditional therapies holds promise for clinical benefit. This review will focus on new agents that are promising and their potential role in the treatment of SCCHN.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 611-619 |
| Number of pages | 9 |
| Journal | Clinical Advances in Hematology and Oncology |
| Volume | 4 |
| Issue number | 8 |
| State | Published - Aug 1 2006 |
| Externally published | Yes |
Keywords
- COX-2
- EGFR
- Head and neck cancer
- Sorafenib
- VEGF
ASJC Scopus subject areas
- Hematology
- Oncology